Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
AstraZeneca, Merck Drop Drug Candidates
by Lisa M. Jarvis
March 26, 2012
| A version of this story appeared in
Volume 90, Issue 13
AstraZeneca and Targacept have dropped development of the antidepressant TC-5214 after it failed to improve depression in a Phase III study. Since learning of the trial results, Targacept has been evaluating the drug’s future. The company has more than $225 million in cash on hand and a pipeline of compounds in Phase II trials. Separately, Merck & Co. has ended development of an oral formulation of vernakalant, for the prevention of atrial fibrillation, because of regulatory challenges. Cardiome Pharma, from which Merck licensed the drug, will conserve cash by cutting annual spending in half.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter